NIH study for SPMS underway on experimental drug Rituximab
Posted: Mon Jan 27, 2014 2:06 am
There are currently no effective treatments for people with secondary-progressive MS who do not experience relapses or who do not have “active” lesions on MRI, however researchers at the National Institutes of Health in Bethesda, Maryland are evaluating the safety and effectiveness of Rituximab (trade names Rituxan and MabThera) – a new experimental drug for treating MS. In this study, Rituximab be delivered intravenously and directly into the cerebrospinal fluid by lumbar puncture of about 80 people with secondary-progressive Multiple Sclerosis. The study is funded by the National Institute of Neurological Disorders and Stroke...... Read More - http://www.ms-uk.org/rituxan